Investor Day Bust: Novo Nordisk Plunges As Wall Street's Turnaround Hopes Fade
Novo Nordisk shares fell as much as 7.7% after analysts questioned its turnaround plans and the loss of its GLP-1 lead to Eli Lilly. The company’s more than $23 billion sales opportunity from over five planned blockbuster launches now faces a higher bar for execution.
At its capital markets day in London, Novo Nordisk set out plans for more than five blockbuster launches and over $23 billion in new sales in the coming years. The presentation came as the stock fell as much as 7.7% in Copenhagen trading, with Wall Street analysts questioning whether the event offered enough detail on the drugmaker’s turnaround efforts.
The central change is competitive: Novo’s lead in the obesity market has been surrendered to Eli Lilly. Analysts had been looking for more commentary from management on how Novo intends to regain momentum, making the launch pipeline and projected sales opportunity the main tests of the new strategy.
Eli Lilly is the company directly connected to the competitive shift. Its FY 2025 revenue was $65.2B, up 44.7% year over year, with a 31.7% net margin and $22.95 diluted EPS, providing a large commercial benchmark as Novo works to rebuild its position in GLP-1 medicines.
The reporting leaves the turnaround response and the pace of the planned launches as the unresolved points. The market reaction indicates that the presentation did not settle analysts’ concerns, but the more than $23 billion sales target remains a concrete measure against which execution can be judged.
The next markers are the timing of those blockbuster launches, the sales generated by them, and evidence that Novo can compete with Eli Lilly in obesity treatments. Future company updates will determine whether the planned launches translate into the projected new sales and whether the lost market lead can be recovered.
Novo Nordisk shares fell 7.7% after analysts questioned its turnaround plans and Eli Lilly took the GLP-1 lead.
The immediate consequence is a credibility gap around Novo’s turnaround: management offered more than five blockbuster launches and over $23 billion in potential new sales, yet the shares fell as much as 7.7% as analysts sought more detail. Eli Lilly’s FY 2025 revenue of $65.2B, up 44.7% year over year, shows the scale of the competitor now setting the commercial benchmark in GLP-1 drugs.
The read fails if Novo’s planned launches arrive on schedule and begin producing the projected sales, or if subsequent updates show a credible path to reclaiming obesity-market momentum.
CoverageSource: ZeroHedge · Published here MON, SEP 21 · 6:55 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
More than five planned blockbuster launches and over $23 billion in prospective new sales give Novo a concrete pipeline through which to rebuild growth.
The 7.7% share-price drop and Eli Lilly’s 44.7% FY 2025 revenue growth show that investors currently see execution and competitive leadership as unresolved.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →